Drugs
Overview
'Drugs' is a peer-reviewed journal that focuses on the latest research and developments in the field of pharmacology and drug discovery. It covers a wide range of topics including drug design, mechanisms of action, clinical trials, and drug safety. With its rigorous scientific approach, 'Drugs' serves as a valuable resource for researchers, clinicians, and pharmaceutical professionals seeking to stay updated on advancements in the world of drugs.
Details
Details
Abbr.
Drugs
Start
1971
End
Continuing
Frequency
24 no. a year, 2003-
p-ISSN
0012-6667
e-ISSN
1179-1950
Country
New Zealand
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 835
188
SJR / Ranks: 912
2352
CiteScore / Ranks: 332
20.40
JIF / Ranks: 354
11.5
Recent Articles
1.
Syed Y
Drugs
. 2025 Mar;
PMID: 40074987
Olezarsen (TRYNGOLZA™) is a first-in-class, GalNAc-conjugated antisense oligonucleotide being developed by Ionis Pharmaceuticals for the treatment of familial chylomicronaemia syndrome (FCS) and severe hypertriglyceridaemia. It binds to apoC-III mRNA, promoting...
2.
Kolkhir P, Fok J, Kocaturk E, Li P, Okas T, Marcelino J, et al.
Drugs
. 2025 Mar;
PMID: 40074986
Chronic spontaneous urticaria (CSU) is a mast cell-mediated skin disease that presents with wheals, angioedema, or both for more than 6 weeks. Less than 10% of patients have complete control...
3.
Syed Y
Drugs
. 2025 Mar;
PMID: 40072775
Revumenib (Revuforj) is an oral, first-in-class menin inhibitor developed by Syndax Pharmaceuticals for the treatment of KMT2A-rearranged (KMT2Ar) acute leukaemia, NPM1-mutated (NPM1m) acute myeloid leukaemia (AML) and solid tumours. The...
4.
Lamb Y
Drugs
. 2025 Mar;
PMID: 40035947
Tasurgratinib succinate (TASFYGO; Eisai Co., Ltd.) is an orally active, small molecule inhibitor of fibroblast growth factor receptors (FGFRs) 1, 2, and 3 being developed for the treatment of solid...
5.
Blair H
Drugs
. 2025 Feb;
PMID: 39994106
Zenocutuzumab (zenocutuzumab-zbco; BIZENGRI), an IgG1 bispecific human epidermal growth factor receptor (HER)2- and HER3-directed antibody, is being developed by Merus for the treatment of solid tumours with neuregulin 1 (NRG1)...
6.
Lombardi C, Comberiati P, Ridolo E, Cottini M, Yacoub M, Casagrande S, et al.
Drugs
. 2025 Feb;
PMID: 39985742
No abstract available.
7.
Tanaka Y
Drugs
. 2025 Feb;
PMID: 39985741
Glucocorticoids (GCs) possess potent anti-inflammatory and immunosuppressive properties and are used to treat various diseases, including systemic autoimmune rheumatic diseases, rheumatoid arthritis, and systemic lupus erythematosus (SLE). However, GCs are...
8.
Silverstein S, Oddone F, Kolko M, Brinkmann C, Christie W, Bicket A, et al.
Drugs
. 2025 Feb;
PMID: 39985740
Background: Bimatoprost implant 10 µg is an intracameral, biodegradable implant that slowly releases bimatoprost to lower intraocular pressure (IOP). This study was designed to evaluate safety and the duration of...
9.
McGovern D, Jones R, Jayne D, Smith R
Drugs
. 2025 Feb;
85(3):325-341.
PMID: 39969779
The complex pathophysiology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) is reflected in the heterogeneity of the presenting clinical syndromes caused by these diseases but also provides a variety of...
10.
Fuggle N, Laslop A, Rizzoli R, Al-Daghri N, Alokail M, Balkowiec-Iskra E, et al.
Drugs
. 2025 Feb;
85(3):343-360.
PMID: 39969778
Osteoporosis and osteoarthritis are key diseases of musculoskeletal ageing and are increasing in prevalence and burden with the progressively ageing population worldwide. These conditions are thus particularly common in 'the...